Connect with us

Life Sciences

STL Expands Its Enterprise Networking Solution Portfolio With Estelan

STL launches Estelan, its end-to-end passive enterprise networking solution portfolio, at GITEX 2023  STL a leading optical and digital solutions company,…

Published

on

This article was originally published by AITHORITY
STL Expands Its Enterprise Networking Solution Portfolio With Estelan
  • STL launches Estelan, its end-to-end passive enterprise networking solution portfolio, at GITEX 2023

 STL a leading optical and digital solutions company, announced the expansion of its Enterprise Networking solutions portfolio with the launch of Estelan. Estelan, an end-to-end solution in fibre and copper cable connectivity, enables enterprises to modernise and digitise their large-scale network infrastructure.

Read: AI and Machine Learning Are Changing Business Forever

Global enterprises will spend $3.4 trillion by 2026 in cloud services, cybersecurity, AI applications, robotics process automation, and Industry 4.0 to create new value sources through digital products and experiences. These digital transformation use cases require an overhaul of enterprise connectivity infrastructure to integrate power and data.

Estelan is an end-to-end enterprise connectivity solution that combines in-office and optical connectivity infrastructure. Its plug-and-play modular system is designed for easy installation and system upgrades and can handle multiple network ports.

These solutions follow the highest health and safety standards and are certified by leading industry bodies like RoHS, ETL, UL, and CPR. STL’s Estelan solution is tailored to suit the needs of multiple industries and offers high flexibility and scalability for their operational environment requirements, be it healthcare, education, retail, banking, oil and gas, and others. With Estelan, enterprises can achieve superior data transmission, upwards of 1000MHz bandwidth and 10Gbps speeds. These solutions have also been designed and developed with sustainable manufacturing practices, high optimisation, and minimal wastage.

Read the latest blogs: Navigating The Reality Spectrum: Understanding VR, AR, and MR

This comprehensive solution enables use cases like multi-service premise connectivity, enterprise networking, Wi-Fi, surveillance, Intelligent building management and Power over Ethernet for up to 90W applications. The company has announced that it will go to market with this solution in its target regions of MEA and India.

Launching Estelan, Gavin Faulds, Regional Sales Head, APAC, and MEA, STL, said: “Enterprises are becoming more connected, intelligent, and agile by leveraging various digital technologies. Through Estelan, we offer customised end-to-end enterprise connectivity solutions that are optimised for their specific business needs. From conceptualisation to installation, we want our customers’ experience to be seamless. Estelan will help them gain a competitive edge by making connectivity infrastructure competent enough for disruptive technologies and drive business transformation.”

Recommended: Tableau + GPT: Ushering into a New Era of AI-led Business Analytics

[To share your insights with us, please write to sghosh@martechseries.com]

The post STL Expands Its Enterprise Networking Solution Portfolio With Estelan appeared first on AiThority.




machine learning

Life Sciences

Wittiest stocks:: Avalo Therapeutics Inc (NASDAQ:AVTX 0.00%), Nokia Corp ADR (NYSE:NOK 0.90%)

There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well…

Continue Reading
Life Sciences

Spellbinding stocks: LumiraDx Limited (NASDAQ:LMDX 4.62%), Transocean Ltd (NYSE:RIG -2.67%)

There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well…

Continue Reading
Life Sciences

Asian Fund for Cancer Research announces Degron Therapeutics as the 2023 BRACE Award Venture Competition Winner

The Asian Fund for Cancer Research (AFCR) is pleased to announce that Degron Therapeutics was selected as the winner of the 2023 BRACE Award Venture Competition….

Continue Reading

Trending